The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Challenges associated with gene therapies for SCD and thalassemia
Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, discusses ongoing challenges with gene therapies for sickle cell disease (SCD) and thalassemia. These include the costly and time-consuming process of stem cell mobilization and the toxic side effects of myeloablative conditioning. Dr Chakravorty emphasizes the need for continuous monitoring of gene therapy side effects and the pursuit of safer gene technologies. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speaker fees from Vertex.
